Attention AACR Annual Meeting 2017 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 27 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 24 25 26 27 presentations: 1 to 25 of 667
Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Howard Burris
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
Ryan J Sullivan
Harvard Medical School/MGH, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Alex A. Adjei
Mayo Clinic, Rochester, MN, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study
Birgit Geoerger
Inst. Gustave Roussy, Villejuif, France
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Yael P Mosse
Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Silvia Marsoni
Grande Ospedale Metropolitano Niguarda, Milano, Italy
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Discussant
Rodrigo Dienstmann
Vall dĀ“Hebron Inst. of Oncology, Barcelona, Spain
from AACR Annual Meeting 2017 on April 2, 2017 12:45 PM-3:00 PM
Introduction
Cornelia Liu Trimble
Johns Hopkins Univ., Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
High-dimensional immune monitoring of tumor tissues for cancer immunotherapy
Sacha Gnjatic
Icahn School of Medicine at Mount Sinai, New York, NY, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
Targeting pathogen-induced malignancies: Lessons learned from adoptive T cell transfer for merkel cell carcinoma
Aude G. Chapuis
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
Developing a biomarker platform to serve targeted therapy and immunotherapy
Keith T Flaherty
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
High-dimensional analyses of the mucosal microenvironment in precancerous, intraepithelial cervical HPV disease
Cornelia L. Trimble
Johns Hopkins Univ., Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 1, 2017 3:15 PM-5:15 PM
Invited Speaker
Peter C. Adamson
Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Invited Speaker
Jeffrey S. Miller
Univ. of Minnesota, Minneapolis, MN, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Invited Speaker
Daniel S. Chen
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multi-center, phase III trial
Roger Stupp
University Hospital Zurich & Northwestern University, Zurich & Chicago, Switzerland
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Panagiotis A Konstantinopoulos
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study
Joyce F Liu
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor
Ruth O'Regan
University of Wisconsin Carbone Cancer Center, Madison, WI, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)
Cynthia Ma
Washington University School of Medicine, St. Louis, MO, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Novel effect of tamoxifen therapy: disruption of ER-p53 interaction leading to altered gene expression profile in human breast tumors
Gokul M. Das
Roswell Park Cancer Inst., Buffalo, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC)
Jame Abraham
NSABP, and The Cleveland Clinic, Cleveland, OH, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Introduction
Thomas Frank Gajewski
Univ. of Chicago, Chicago, IL, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
<< first | < prev page: of 27 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 24 25 26 27 presentations: 1 to 25 of 667